Abeona Therapeutics
Logotype for Abeona Therapeutics Inc

Abeona Therapeutics (ABEO) investor relations material

Abeona Therapeutics Morgan Stanley 24th Annual Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Abeona Therapeutics Inc
Morgan Stanley 24th Annual Global Healthcare Conference summary16 Sep, 2026

Company transition and product launch

  • Transitioned from R&D to commercial stage after first product approval in late 2025, expanding from 80–90 to 250 employees and establishing GMP manufacturing and supply.

  • ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic EB, launched in December 2025, offering multi-year wound healing from a single application.

  • Unique launch challenges include ultra-rare disease focus, 84-hour product shelf life, and need for multidisciplinary treatment centers.

  • Launch strategy emphasizes foundation building, site activation, and patient ambassador networks to support adoption.

  • Commercially treated patients often previously used VYJUVEK, highlighting ZEVASKYN’s differentiated value for large, chronic wounds.

Market landscape and differentiation

  • ZEVASKYN addresses a severe genetic disorder with high morbidity and mortality, offering a durable, one-time treatment compared to weekly alternatives.

  • Both ZEVASKYN and VYJUVEK are needed for different wound types; ZEVASKYN is suited for large, contiguous wounds.

  • Clinical data show up to 12 years of wound healing from a single application, supporting its unique value proposition.

Commercialization and operational learnings

  • Launch requires coordination among surgeons, anesthesiologists, and EB physicians at qualified centers, with each site needing to replicate clinical success.

  • Patient-to-patient communication and ambassador programs are key to building trust and awareness.

  • Initial bottlenecks vary by institution, often related to payer mix and institutional learning curves; cross-pollination of best practices is ongoing.

  • Leading indicators for launch momentum include number of centers, treated patients, and patient interest; 40% of the addressable market is now within reach of a qualified center.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Abeona Therapeutics earnings date

Logotype for Abeona Therapeutics Inc
Stifel 2026 Healthcare Conference 202611 Nov, 2026
Abeona Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Abeona Therapeutics earnings date

Logotype for Abeona Therapeutics Inc
Stifel 2026 Healthcare Conference 202611 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. The company's initial focus is on amyotrophic lateral sclerosis therapy based on the conversion of skin cells into motor neurons. Furthermore, the company is developing TAHO, an attenuated adenovirus that is administered orally, for the treatment of patients who have severe combined immunodeficiency (SCID-X1), a rare genetic disease that causes immune system deficiency and increases susceptibility to infection in early childhood.